The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade

• Published in: Molecular genetics and metabolism Vol. 110; no. 3; pp. 311 - 318
• Main Authors: Bigg, Paul W., Sleeper, Meg M., O'Donnell, Patricia A., Liu, Yuli, Wu, Susan, Casal, Margret L., Haskins, Mark E., Ponder, Katherine P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2013
• Subjects: Animals; Animals, Newborn; Aortic Valve - diagnostic imaging; Aortic Valve - pathology; Cardiac disease; Disease Models, Animal; Dogs; Echocardiography; Female; Gammaretrovirus - genetics; Gene therapy; Genetic Therapy; Genetic Vectors - genetics; Glucuronidase - genetics; Glucuronidase - metabolism; Heart Valve Diseases - diagnostic imaging; Heart Valve Diseases - etiology; Heart Valve Diseases - therapy; Lysosomal storage disease; Male; Mitral Valve - diagnostic imaging; Mitral Valve - pathology; Mucopolysaccharidosis; Mucopolysaccharidosis VII - complications; Mucopolysaccharidosis VII - genetics; Retroviral vector; Retroviral vector; Mucopolysaccharidosis; Lysosomal storage disease; Gene therapy; Cardiac disease
• DOI: 10.1016/j.ymgme.2013.06.015
• ISSN: 1096-7192

Mucopolysaccharidosis VII (MPS VII) is due to deficient activity of the lysosomal enzyme β-glucuronidase (GUSB) and results in the accumulation of glycosaminoglycans (GAGs). This study determined the long-term effect of neonatal intravenous injection of a gamma retroviral vector (RV) on cardiac valve disease in MPS VII dogs. Transduced hepatocytes secreted GUSB into the blood for up to 11years at levels similar to or greater than those achieved with enzyme replacement therapy (ERT). Valve regurgitation and thickening were scored from 0 (normal) to +4 (severely abnormal). At 1year, untreated MPS VII dogs had mitral regurgitation, mitral valve thickening, aortic regurgitation, and aortic valve thickening scores of 2.3±0.7, 2.3±0.6, 1.8±0.5, and 1.6±0.7, respectively, which were higher than the values of 0.6±0.1, 0.1±0.4, 0.3±0.8, and 0.1±0.4, respectively, in treated MPS VII dogs. Treated MPS VII dogs maintained low aortic regurgitation and aortic valve thickening scores in their lifetime. Although mitral regurgitation and mitral valve thickening scores increased to 2.0 at ≥8years of age in the treated MPS VII dogs, older normal dogs from the colony had similar scores, making it difficult to assess mitral valve disease. Older treated dogs had calcification within the mitral and the aortic valve annulus, while GUSB staining demonstrated enzyme activity within the mitral valve. We conclude that neonatal RV-mediated gene therapy reduced cardiac valve disease in MPS VII dogs for up to 11years, and propose that neonatal initiation of ERT should have a similar effect. •Neonatal gene therapy reduces mitral valve disease in MPS VII dogs for 7years.•Neonatal gene therapy reduces aortic valve disease in MPS VII dogs for 11years.•Results predict that initiation of ERT at birth will reduce heart disease long-term.